1-甲基-3-三氟甲基-1H-吡唑 | 154471-65-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-3-三氟甲基-1H-吡唑
• 中文别名: 1-甲基-3-(三氟甲基)吡唑
• 英文名称: 1-methyl-3-(trifluoromethyl)-1H-pyrazole
• 英文别名: 1-methyl-3-(trifluoromethyl)pyrazole；1-methyl-3-trifluoromethylpyrazol
• CAS: 154471-65-5
• 化学式: C₅H₅F₃N₂
• 分子量: 150.103
• InChiKey: MQSLINQSJFALSP-UHFFFAOYSA-N

物化性质

• 沸点：
  137.7±35.0 °C(Predicted)
• 密度：
  1.32g/ml

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  | 室温 干燥 |

SDS

Name:	1-Methyl-3-(trifluoromethyl)-1H-pyrazole 97% Material Safety Data Sheet
Synonym:
CAS:	154471-65-5

Section 1 - Chemical Product MSDS Name:1-Methyl-3-(trifluoromethyl)-1H-pyrazole 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
154471-65-5	1-Methyl-3-(trifluoromethyl)-1H-pyrazo	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 154471-65-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 82 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H5F3N2
Molecular Weight: 150.1

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 154471-65-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-3-(trifluoromethyl)-1H-pyrazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 154471-65-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 154471-65-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 154471-65-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用1-甲基-3-三氟甲基-1H-吡唑是一种常用的有机合成中间体和医药中间体，在实验室研发和化工生产中发挥着重要作用。

反应信息

• 作为反应物：
  描述：

  1-甲基-3-三氟甲基-1H-吡唑 在 溴 、 叔丁基锂 、 铁粉 作用下， 以 乙醚 、 正戊烷 为溶剂， 反应 4.08h， 生成 1-甲基-3-三氟甲基-1H-吡唑-4-羧酸
  参考文献：
  名称：

  可切换的反应性：三氟甲基取代吡唑的位点选择性功能化

  摘要：

  现代有机金属方法能够将简单的杂环起始材料区域灵活地转化为异构体和同系物家族。取决于试剂的选择，1-甲基-5-(三氟甲基)吡唑主要或仅在杂环的4-位或在氮连接的Me基团上经历去质子化和随后的羧化。类似地，1-苯基-5-(三氟甲基)吡唑和3-甲基-1-苯基-5-(三氟甲基)吡唑在杂环4-位被二异丙基氨基锂选择性攻击，在4-位被丁基锂和Ph 环的正交位置。相比之下，1-甲基-3-（三氟甲基）吡唑的金属化仅发生在 5 位，无论是有机金属碱还是金属氨化物碱。如果将溴引入杂环或芳基中，则其他位点可进行功能化。戒指。4-溴-1-甲基-5-（三氟甲基）吡唑、4-溴-1-甲基-3-（三氟甲基）吡唑、4-溴-1-甲基-5-（三氟甲基）吡唑和1-(2-溴苯基)-5-(三氟甲基)吡唑。[在 SciFinder (R) 上]

  DOI：

  10.1002/1099-0690(200209)2002:17<2913::aid-ejoc2913>3.0.co;2-d
• 作为产物：
  描述：

  4-Butoxy-2,2,4-trichloro-1,1,1-trifluorobutane 、 甲基肼 在 溶剂黄146 作用下， 以 水 为溶剂， 反应 1.0h， 以85%的产率得到1-甲基-3-三氟甲基-1H-吡唑
  参考文献：
  名称：

  一种吡唑类化合物的制备方法

  摘要：

  本发明公开了一种吡唑类化合物的制备方法。该方法包括：方法A：溶剂中，将如式(II‑A)所示的化合物与如式(III)所示的化合物进行环合反应，制得如式(I)所示的化合物；方法B：溶剂中，将如式(II‑B)所示的化合物与如式(III)所示的化合物环合反应，制得如式(I)所示的化合物。本发明的制备方法原料廉价易得、生产成本低、反应条件温和、操作简单、目标化合物收率和纯度高、绿色环保，更适用于工业化生产。

  公开号：

  CN106916107B

文献信息

• [EN] DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERTO<br/>[FR] DERIVES DE DIARYL ET ARYLHETEROARYL UREE UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DE LA SEROTONINE 5-HT2A UTILES POUR LA PROPHYLAXIE ET LE TRAITEMENT DE TROUBLES ASSOCIES A CE DERNIER
  申请人：ARENA PHARM INC

  公开号：WO2005012254A1

  公开（公告）日：2005-02-10

  The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

  本发明涉及某些Formula (I)的吡唑衍生物及其药物组合物，可调节5-HT2A 5-羟色胺受体的活性。该类化合物及其药物组合物用于预防或治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、心房颤动、减少血凝块形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、吉尔·德·拉·图雷特综合征、躁狂症、器质性或NOS精神病、精神病性障碍、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、睡眠障碍、糖尿病相关疾病等的方法。本发明还涉及预防或治疗5-HT2A 5-羟色胺受体介导的疾病的方法，结合多巴胺D2受体拮抗剂如氟哌啶醇，分别或联合给药。
• [EN] IONIC LIQUIDS, METHOD FOR MANUFACTURING THEREOF, AND ELECTROCHEMICAL DEVICES COMPRISING THE SAME<br/>[FR] LIQUIDES IONIQUES, LEUR PROCÉDÉ DE FABRICATION ET DISPOSITIFS ÉLECTROCHIMIQUES LES COMPRENANT
  申请人：SOLVAY

  公开号：WO2013167586A1

  公开（公告）日：2013-11-14

  The present invention concerns ionic liquids comprising at least one pyrazolium cation which are substituted by at least one fluorine atom and at least one anion obtainable from 4-ethoxy- 1,1,1 -trifluoro-3-butene-2-one (ETFBO). The ionic liquids according to the present invention can be used as electrolytes for electrochemical and/or optoelectronic devices.

  本发明涉及至少含有一个由至少一个氟原子取代的吡唑阳离子和至少一个可从4-乙氧基-1,1,1-三氟丙烯-2-酮（ETFBO）获得的阴离子的离子液体。根据本发明的离子液体可用作电化学和/或光电子器件的电解质。
• Ionic Liquids, Method for manufacturing thereof, and Electrochemical Devices Comprising the Same
  申请人：SOLVAY SA

  公开号：EP2662359A1

  公开（公告）日：2013-11-13

  The present invention concerns ionic liquids comprising at least one pyrazolium cation which are substituted by at least one fluorine atom and at least one anion obtainable from 4-ethoxy-1,1,1-trifluoro-3-butene-2-one (ETFBO). The ionic liquids according to the present invention can be used as electrolytes for electrochemical and/or optoelectronic devices.

  这项发明涉及至少含有一个由至少一个氟原子取代的吡唑阳离子和至少一个可从4-乙氧基-1,1,1-三氟-3-丁烯-2-酮（ETFBO）获得的阴离子的离子液体。根据本发明的离子液体可用作电化学和/或光电子器件的电解质。
• 4-Methylsulfonyl-Substituted Piperidine Urea Compounds
  申请人：MyoKardia, Inc.

  公开号：US20160243100A1

  公开（公告）日：2016-08-25

  The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

  本发明提供了一种新颖的4-甲基砜取代哌啶脲化合物，可用于治疗扩张型心肌病（DCM）以及与左心室和/或右心室收缩功能障碍或收缩储备相关的疾病。描述了这些化合物的合成和表征，以及治疗DCM和其他形式心脏疾病的方法。
• <scp>Palladium‐catalyzed</scp> Aerobic Benzannulation of Pyrazoles with Alkynes
  作者：Jae Yeong Song、Jin Hyeok Jang、Shih‐Ching Chuang、Jung Min Joo

  DOI：10.1002/bkcs.12175

  日期：2021.3

  stoichiometric metal oxidant, oxygen was used as an oxidant for Pd‐catalyzed annulation reactions of pyrazoles with internal alkynes. The addition of sodium acetate and acetic acid was critical for stabilizing the Pd system. This green approach allowed the preparation of indazoles from readily available parent pyrazoles in a single step.

  作为化学计量金属氧化剂的替代品，氧气被用作吡唑与内部炔烃的钯催化环化反应的氧化剂。添加乙酸钠和乙酸对于稳定Pd系统至关重要。这种绿色方法可以一步一步从容易获得的母体吡唑制备吲唑。